12 月 9日，可孚医疗与皇家飞利浦（Royal Philips）正式签署战略合作协议。双方将围绕多款家庭健康监测设备开展深度合作，让高品质健康科技产品 更广泛地进入中国家庭。 根据协议，可孚医疗将获得皇家飞利浦多款家庭健康监测设备中国地区的品牌授权，包括血糖仪、血压计、持续葡萄糖监测仪（CGM）、体温计、脉 搏血氧仪、肺功能仪、体重秤等产品。双方将共同推进相关产品的技术研发、本地化适配与迭代升级，并由可孚医疗全面负责其在中国的生产制造、品牌运 营、渠道布局与服务体系建设，实现研发创新与产业能力的深度融合。 此次合作是国际知名品牌与中国本土龙头企业在技术、品牌与产业链能力上的深度协同。双方将整合飞利浦的百年科技积淀、全球品牌资源与临床技术 优势，叠加可孚医疗在创新研发、智能制造、渠道运营等方面的综合实力，共同构建面向中国家庭的智慧健康管理生态。 飞利浦是全球领先的健康科技企业，长期致力于通过创新提升人们的健康与福祉。依托先进技术与深厚的临床技术沉淀和消费者洞察，为消费者提供个 人健康解决方案，并为医疗服务提供者及其在医院和家庭场景中的患者提供专业医疗解决方案。除自有产品外，飞利浦还通过严格筛选的品牌授权合作伙 ...

据悉，首批飞利浦智能监测医疗设备已进入上市筹备阶段，将以更具创新性和前瞻性的产品方案服务广 大消费者。未来，将通过强化线上渠道布局巩固市场领先优势，并依托自有零售体系、全国及区域分销 网络、头部连锁药店、医疗器械专营店及诊所等多元渠道，实现业务的快速拓展与覆盖。 皇家飞利浦是全球领先的健康科技企业，长沙上市公司可孚医疗是中国最大的家用医疗器械企业之一。 根据协议，可孚医疗将获得皇家飞利浦多款家庭健康监测设备中国地区的品牌授权，包括血糖仪、血压 计、持续葡萄糖监测仪、体温计、脉搏血氧仪、肺功能仪、体重秤等。双方将共同推进相关产品的技术 研发、本地化适配与迭代升级，并由可孚医疗全面负责其在中国的生产制造、品牌运营、渠道布局与服 务体系建设，实现研发创新与产业能力的深度融合。 长沙晚报12月9日讯（全媒体记者 曹开阳）9日，可孚医疗与皇家飞利浦（Royal Philips）签署战略合作 协议。双方将围绕多款家庭健康监测设备开展深度合作，让高品质健康科技产品更广泛地进入中国家 庭。省商务厅副厅长刘素月，副市长郑平参加签约仪式。 ...

中证报中证网讯(王珞)12月9日，可孚医疗（301087）与皇家飞利浦(Royal Philips)签署战略合作协议， 双方将围绕多款家庭健康监测设备开展深度合作，让高品质健康科技产品更广泛地进入中国家庭。 分析人士认为，双方合作是国际领先品牌与国内龙头企业的优势互补。此次合作将在技术标准、产品创 新、服务质量等方面树立行业新标杆，助力先进医疗设备产品更快、更广泛、更可靠地进入中国家庭， 为健康中国建设注入新动力。 据悉，首批飞利浦智能监测医疗设备已进入上市筹备阶段，将以更具创新性和前瞻性的产品方案服务广 大消费者。未来，相关产品将通过强化线上渠道布局巩固市场领先优势，并依托自有零售体系、全国及 区域分销网络、头部连锁药店、医疗器械专营店及诊所等多元渠道，实现业务的快速拓展与覆盖，让协 同创新的健康科技惠及更广泛的用户群体。 根据协议，可孚医疗将获得皇家飞利浦多款家庭健康监测设备中国地区的品牌授权，包括血糖仪、血压 计、持续葡萄糖监测仪(CGM)、体温计、脉搏血氧仪、肺功能仪、体重秤等产品。双方将共同推进相关 产品的技术研发、本地化适配与迭代升级，并由可孚医疗全面负责其在中国的生产制造、品牌运营、渠 道布局与 ...

12月9日，中国家用医疗器械领军企业可孚医疗（301087）与皇家飞利浦（Royal Philips）正式签署战略 合作协议。双方将围绕多款家庭健康监测设备开展深度合作，让高品质健康科技产品更广泛地进入中国 家庭。 根据协议，可孚医疗将获得皇家飞利浦多款家庭健康监测设备在大中华区（覆盖中国大陆、香港、澳门 及台湾地区）的品牌授权，包括血糖仪、血压计、持续葡萄糖监测仪（CGM）、体温计、脉搏血氧 仪、肺功能仪、体重秤等产品。可孚医疗将负责产品的本地化运营、市场推广与服务体系建设。 国际品牌与本土龙头双向赋能 此次合作是国际知名品牌与中国本土龙头企业在技术、品牌与产业链能力上的深度协同。双方将整合飞 利浦的百年科技积淀、全球品牌资源与临床技术优势，叠加可孚医疗在创新研发、智能制造、渠道运营 等方面的综合实力，共同构建面向中国家庭的智慧健康管理生态。 皇家飞利浦是全球领先的健康科技企业，长期致力于通过创新提升人们的健康与福祉。依托先进技术与 深厚的临床技术沉淀和消费者洞察，为消费者提供个人健康解决方案，并为医疗服务提供者及其在医院 和家庭场景中的患者提供专业医疗解决方案。除自有产品外，飞利浦还通过严格筛选的品牌授权 ...

可孚医疗董事长张敏表示，感谢飞利浦对可孚在研发、生产、渠道等方面综合能力的认可与信任。可孚 医疗将依托本地化生产能力及全链条运营优势，持续提升产品品质、优化用户体验，为中国家庭提供更 专业、精准的健康监测解决方案。 长沙晚报掌上长沙12月9日讯（全媒体记者 曹开阳）12月9日，中国家用医疗器械领军企业、长沙上市 公司可孚医疗与皇家飞利浦（Royal Philips）正式签署战略合作协议。双方将围绕多款家庭健康监测设 备开展深度合作，让高品质健康科技产品更广泛地进入中国家庭。 根据协议，可孚医疗将获得皇家飞利浦多款家庭健康监测设备中国地区的品牌授权，包括血糖仪、血压 计、持续葡萄糖监测仪（CGM）、体温计、脉搏血氧仪、肺功能仪、体重秤等产品。双方将共同推进 相关产品的技术研发、本地化适配与迭代升级，并由可孚医疗全面负责其在中国的生产制造、品牌运 营、渠道布局与服务体系建设，实现研发创新与产业能力的深度融合。 强强联合 国际品牌与本土龙头双向赋能 此次合作是国际知名品牌与中国本土龙头企业在技术、品牌与产业链能力上的深度协同。双方将整合飞 利浦的百年科技积淀、全球品牌资源与临床技术优势，叠加可孚医疗在创新研发、智能 ...

本报讯(记者何文英)近日，国内家用医疗器械领军企业可孚医疗（301087）科技股份有限公司(简称"可 孚医疗")在生物传感技术领域取得重要突破，其研究成果以《Single-channel electrochemical biosensor for simultaneous monitoring of glucose and uric acid》(用于同步检测葡萄糖和尿酸的单通道电化学生物传感 器)为题，发表在生物传感领域国际顶级期刊《Biosensors and Bioelectronics》。 论文第一作者为可孚医疗生物传感与创新材料研究院副院长全昌云，通讯作者为徐斌杰院长和阳明辉教 授。这是可孚医疗科研团队首次在国际顶级期刊发表科研论文，标志着企业在关键核心传感技术自主创 新上实现重大进展。 据了解，《Biosensors and Bioelectronics》是英国出版商Elsevier旗下具有高影响力的国际期刊，也是生 物技术与生物传感器领域排名靠前的核心期刊，影响因子为10.5，SCI一区。 攻克单通道双指标检测难题 当前，我国糖尿病和高尿酸血症(痛风)患者规模庞大，不少人长期面临"双高"风险。传统 ...

Core Insights - The company Kefu Medical closed at 44.99 yuan on December 3, with a 3.62% increase, and a rolling PE ratio of 29.36, marking a new low in 16 days, with a total market capitalization of 9.398 billion yuan [1] - In the medical device industry, the average PE ratio is 51.40, with a median of 39.68, placing Kefu Medical at the 60th position in the industry ranking [1] - As of the Q3 2025 report, 10 institutions hold shares in Kefu Medical, with a total of 112.9708 million shares valued at 4.451 billion yuan [1] Company Overview - Kefu Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, focusing on health monitoring, rehabilitation aids, medical care, respiratory support, and traditional Chinese medicine therapy [1] - The company has received several accolades, including the establishment of a national postdoctoral research station and recognition as a national intellectual property advantage enterprise and a national-level industrial design center [1] Financial Performance - For the Q3 2025 report, Kefu Medical achieved a revenue of 2.398 billion yuan, reflecting a year-on-year increase of 6.63%, and a net profit of 260 million yuan, up 3.30% year-on-year, with a gross profit margin of 53.35% [2] - The PE ratio (TTM) for Kefu Medical is 29.36, while the static PE is 30.15, and the price-to-book ratio is 1.99 [2]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Core Viewpoint - The article highlights the collective efforts of Hunan enterprises and individuals in response to a significant fire incident in Hong Kong, showcasing solidarity and support for the affected community [1]. Group 1: Donations and Contributions - Multiple Hunan enterprises have actively participated in fundraising efforts, with the Hong Kong Hunan Association and 21 member organizations expected to donate 5 million HKD [2]. - Notable contributions include: - Lens Technology donating 13.1 million HKD - SANY Group donating 10 million HKD and providing energy equipment for emergency power supply - Afuni Future Capital donating 10 million HKD - Other companies like Zhongwei New Materials, Simore International, and Aier Eye Hospital each donating 5 million HKD [2]. - Additional donations include 2 million RMB from Yanjin Puzhi Food Co., 1 million HKD from Wanxing Technology, and 200,000 RMB from SHOWVEN [2]. Group 2: Individual Contributions - Several Hunan entrepreneurs have also made personal donations, including: - Hu Guoan, Vice President of the Hong Kong Hunan Association, donating 1 million RMB - Lian Zhen'en, Executive President of the association, donating 300,000 HKD - Other individuals contributing smaller amounts [3]. - SANY Group has activated a global disaster response mechanism to assist affected individuals [3]. Group 3: Call for Support and Initiatives - The Hong Kong Hunan Association has initiated a fundraising campaign, encouraging the community to donate cold-weather relief supplies and seek assistance if needed [4]. - The Changsha Municipal Federation of Industry and Commerce and the Changsha Guangcai Foundation have issued a call to action for local businesses to contribute to the relief efforts, emphasizing the importance of social responsibility [4].

Group 1 - A level 5 fire occurred in Hong Kong's Tai Po district, resulting in significant casualties and property damage [1] - Kefu Medical Technology Co., Ltd. and its Hong Kong subsidiary, Humana Medical Limited, donated HKD 2 million in cash and HKD 3 million worth of medical supplies to support the disaster relief efforts [1] - The company expressed its commitment to closely monitor the disaster situation and collaborate with various sectors of Hong Kong society for the reconstruction and recovery of the affected areas [1]